Anti-estrogen‑resistant breast cancer cells are sensitive to cisplatin plus TRAIL treatment

  • Authors:
    • Shuping Yin
    • Arun K. Rishi
    • Kaladhar B. Reddy
  • View Affiliations

  • Published online on: January 14, 2015     https://doi.org/10.3892/or.2015.3721
  • Pages: 1475-1480
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer patients who are positive for estrogen receptor (ER) are usually treated with anti-estrogen drugs, such as tamoxifen (Tam). However, a great majority of such patients eventually develop resistance to Tam. In this study, MCF-7 cells (with de novo and/or acquired resistance to Tam) as well as T47D cells (acquired resistance to Tam) models were used to investigate the effect of treatment with cisplatin plus tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). The results in the two cell types treated with cisplatin plus TRAIL showed significantly increased cell death compared to that in the untreated control cells. A similar treatment had a minimal effect on normal breast cells, the increased cell death appeared to be caused by the activation of caspases and, inhibition of the activity of caspases (using relatively specific inhibitors) reduced the cell death caused by cisplatin plus TRAIL treatment. Taken together, the results suggested that cisplatin plus TRAIL treatment has the potential to provide a novel treatment strategy to improve the treatment outcome in anti-estrogen‑resistant breast cancer patients.
View Figures
View References

Related Articles

Journal Cover

March-2015
Volume 33 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yin S, Rishi AK and Reddy KB: Anti-estrogen‑resistant breast cancer cells are sensitive to cisplatin plus TRAIL treatment. Oncol Rep 33: 1475-1480, 2015
APA
Yin, S., Rishi, A.K., & Reddy, K.B. (2015). Anti-estrogen‑resistant breast cancer cells are sensitive to cisplatin plus TRAIL treatment. Oncology Reports, 33, 1475-1480. https://doi.org/10.3892/or.2015.3721
MLA
Yin, S., Rishi, A. K., Reddy, K. B."Anti-estrogen‑resistant breast cancer cells are sensitive to cisplatin plus TRAIL treatment". Oncology Reports 33.3 (2015): 1475-1480.
Chicago
Yin, S., Rishi, A. K., Reddy, K. B."Anti-estrogen‑resistant breast cancer cells are sensitive to cisplatin plus TRAIL treatment". Oncology Reports 33, no. 3 (2015): 1475-1480. https://doi.org/10.3892/or.2015.3721